title: Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS.
abstract: BACKGROUND
  Fuzeon (enfuvirtide) (ENF) is the first drug among the HIV fusion inhibitors that has shown high efficacy in HIV-1/AIDS patients resistant to conventional antiretroviral agents.
  
  
  OBJECTIVE
  To analyze the cost-effectiveness of ENF plus optimized therapy (OT) in HIV patients.
  
  
  METHODS
  A Markov model was used to calculate the cost-effectiveness of ENF in terms of incremental cost per life-year gained. The model has a 10-year horizon, with monthly cycles, and the perspective is the Spanish National Health System. Efficacy rates and transition probabilities were obtained from clinical and epidemiological trials. Resource use data were retrieved from published literature and a panel of clinicians. Unit costs refer to the year 2003.
  
  
  METHODS
  Incremental cost-effectiveness ratio.
  
  
  RESULTS
  Adding ENF to OT increased patient life expectancy by 1.6 years (6.2 years with OT compared with 7.8 years with ENF + OT). Total costs were 160,728 euro for OT and 200,859 euro with ENF + OT, mainly due to increasing life expectancy raising resource use and costs. Incremental cost per life-year gained with ENF was 25,082 euro.
  
  
  CONCLUSIONS
  ENF plus OT increased life expectancy for HIV-1-treated patients and is an efficient treatment option.
authors.affiliation: Health Economics & Outcomes Research, IMS Health, Barcelona, Spain. xbadia@es.imshealth.com
authors.forename: X
authors.initials: X
authors.lastname: Badia
authors.forename: L
authors.initials: L
authors.lastname: Lizán
authors.forename: S
authors.initials: S
authors.lastname: Magaz
authors.forename: Alvarez C
authors.initials: AC
authors.lastname: Sanz
authors.forename: J
authors.initials: J
authors.lastname: Green
authors.forename: D
authors.initials: D
authors.lastname: Serrano
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000191:economics*; D018791:CD4 Lymphocyte Count; D003362:Cost-Benefit Analysis; D000077560:Enfuvirtide; D006678:HIV; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008017:Life Expectancy; D008390:Markov Chains; D010446:Peptide Fragments / Q000627:therapeutic use*
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide